Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada
- PMID: 34244723
- PMCID: PMC8406884
- DOI: 10.1093/cid/ciab616
Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada
Erratum in
-
Correction to: Single-Dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Alpha and Gamma Variants: A Test-Negative Design in Adults 70 Years and Older in British Columbia, Canada.Clin Infect Dis. 2023 Apr 3;76(7):1347. doi: 10.1093/cid/ciac607. Clin Infect Dis. 2023. PMID: 36921068 Free PMC article. No abstract available.
Abstract
Background: Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥ 70 years old in British Columbia, Canada, where second doses were deferred by up to 16 weeks and where a spring 2021 wave uniquely included codominant circulation of Alpha (B.1.1.7) and Gamma (P.1) variants of concern (VOC).
Methods: Analyses included community-dwelling adults ≥ 70 years old with specimen collection between 4 April (epidemiological week 14) and 1 May (week 17) 2021. Adjusted VE was estimated by test-negative design. Cases were reverse-transcription polymerase chain reaction (RT-PCR) test-positive for SARS-CoV-2, and controls were test-negative. Vaccine status was defined by receipt of a single-dose ≥ 21 days before specimen collection, but a range of intervals was assessed. Variant-specific VE was estimated against viruses genetically characterized as Alpha, Gamma or non-VOC lineages.
Results: VE analyses included 16 993 specimens: 1226 (7%) test-positive cases and 15 767 test-negative controls. Of 1131 (92%) genetically characterized viruses, 509 (45%), 314 (28%), and 276 (24%) were Alpha, Gamma, and non-VOC lineages, respectively. At 0-13 days postvaccination, VE was negligible at 14% (95% confidence interval [CI], 0-26) but increased from 43% (95% CI, 30-53) at 14-20 days to 75% (95% CI, 63-83) at 35-41 days postvaccination. VE at ≥ 21 days postvaccination was 65% (95% CI, 58-71) overall: 72% (95% CI, 58-81), 67% (95% CI, 57-75), and 61% (95% CI, 45-72) for non-VOC, Alpha, and Gamma variants, respectively.
Conclusions: A single dose of mRNA vaccine reduced the risk of SARS-CoV-2 by about two-thirds in adults ≥ 70 years old, with protection only minimally reduced against Alpha and Gamma variants.
Keywords: SARS-CoV-2; case-control; test-negative design; vaccine effectiveness; variants of concern.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures


References
-
- National Advisory Committee on Immunization (NACI). Recommendations on the use of COVID-19 vaccines. Ottawa: NACI. Available at: https://www.canada.ca/en/public-health/services/immunization/national-ad.... Accessed 27 June 2021.
-
- Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Eng J Med 2021; 384:10.1056/NEJMc2036242#sa1. - PubMed
-
- Joint Committee on Vaccination and Immunisation (JCVI). Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination. JCVI; 20 Dec 2020. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploa.... Accessed 27 June 2021.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous